Frontier IP Group Plc, through its subsidiaries, identifies and evaluates commercialization of intellectual property generated by academics, universities, and other partners in the United Kingdom. It also provides investment advisory and marketing services. The company was incorporated in 2007 and is based in London, the United Kingdom.

Frontier IP Group Plc

Frontier IP Group Plc focuses on commercialising intellectual property from research, utilizing expertise in various fields to co-found and develop innovative businesses.

Frontier IP Group plc | 922 followers on LinkedIn. We build value by uniting science, industry and finance to commercialise university intellectual property | Frontier IP specialises in the commercialisation of 
Intellectual Property (IP).
 
Frontier IP establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and help maximise the commercial value of technologies emerging from their research programmes.
 
Frontier IP Group plc is quoted on the AIM market.

Independent Non-Executive Director

Nigel Grierson

Chief Commercialisation Officer at Frontier IP Group plc

Matthew White

Wilson BioPharma Consulting

Campbell Wilson

Finance Director at Frontier IP Group plc

Jim Fish

Frontier IP Group plc

The Vaccine Group and the UK government's Animal and Plant Health Agency have been awarded an Innovate UK Smart grant to develop vaccines against two commercially damaging cattle diseases. Watch TVG CEO Dr Jeremy Salt discuss the project and other developments at the company. #brsv #lumpyskindisease TVG #animalhealth https://lnkd.in/eH2BQ5hj

Great to see our portfolio company The Vaccine Group partnering with the UK government's Animal and Plant Health Agency. They have been awarded an Innovate UK Smart grant to develop cattle vaccines. Initial target diseases are bovine respiratory syncytial virus (BRVS) and lumpy skin disease. Both cause significant economic damage to beef and dairy farmers worldwide. You can learn more here: https://lnkd.in/eHGdMk4q #iuk #innovateuk #brsv #lumpyskindisease #apha #defra

Watch The Vaccine Group CEO Jeremy Salt discuss how a UK government grant will help the company and its partners at the University of Plymouth and the University of Cambridge tackle a bacterial disease in pigs that can also prove fatal in humans. https://lnkd.in/e5vSs-7F #streptococcus #tvg #zoonotic

Our portfolio company The Vaccine Group has teamed up with the University of Plymouth and the University of Cambridge to develop a vaccine to combat a widespread, economically harmful and zoonotic pig disease, which can be fatal to humans. Streptococcus suis is a bacterial infection which is endemic in the global pig population. It can cause meningitis and sceptacaemia in humans. The project is being supported by a grant of more than £1 million from Defra 's Farming Innovation Programme, delivered by Innovate UK. #innovateUK #defra #streptococcus #vaccines #tvg https://lnkd.in/e45pFxRE

We are delighted that Nesta Impact Investments, the investment arm of UK social innovation agency Nesta, has supported our portfolio company Nandi Proteins. Nesta #foodingredients #innovation https://lnkd.in/e7RviH6g

Watch Pulsiv Chief Product Officer Dr Tim Moore discuss the potential for the company's groundbreaking technology with Proactive's Stephen Gunnion: https://lnkd.in/gfC9YkMX #usbc #energyefficiency #pulsiv Proactive Oakglen Wealth Tim tells Proactive’s Stephen Gunnion about the groundbreaking technology behind its latest release—the world’s most efficient 65-watt USB-C reference design charger. Moore detailed how Pulsiv’s focus on maximising power conversion efficiency has led to a cooler-running, more reliable charging solution. He emphasised that the charger’s design, which significantly reduces inrush current, ensures both the safety and longevity of the product, making it ideal for in-socket applications. Tim also discussed the broader market potential, especially as new EU regulations make USB-C connectors mandatory across a wide range of devices. Pulsiv’s technology not only supports these evolving standards but also positions itself as a key player in the fast-growing fast-charger market. As Tim explained, consumers are likely to demand faster charging times across various cordless products, driving the need for high-power USB-C supplies like Pulsiv’s 65W charger. In addition to USB-C applications, Moore hinted at future advancements in AC to DC conversion, which could impact sectors like solar power generation. The conversation highlights Pulsiv’s innovative approach to power conversion, promising a safer and more efficient future for electronic devices.

Listen to Pulsiv chairman Mark Gerhard explain why he thinks the company is Arm 2.0 at an Oakglen Wealth Invest in Innovation seminar earlier this year: https://lnkd.in/gUyzq7Gs Pulsiv has launched the world's most efficient 65W USB-C charger reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. But Pulsiv's underlying technology can be used much more widely, to improve the efficiency of power conversion across a host of different applications. It can also boost output from solar cells. #usbc #energyefficiency

Our portfolio company Pulsiv is today launching the world's most efficient 65W USB-C reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. #pulsiv #usb -c #energyefficiency https://lnkd.in/eGrYDFeA

	Jun '14	Jun '15	Jun '16	Jun '17	Jun '18	Jun '19	Jun '20	Jun '21	Jun '22	Jun '23
net income	27K -	647K 2,296.30%	1.13M 74.81%	1.23M 8.66%	902K 26.61%	2.35M 160.53%	4.18M 78.04%	10.24M 144.79%	10.88M 6.22%	-4.37M 140.17%
depreciation and amortization	1K -	2K 100%	2K 0%	2K 0%	5K 150%	6K 20%	6K 0%	6K 0%	8K 33.33%	9K 12.50%
deferred income tax	-608K -				-2.06M -	-3.85M 86.63%	-5.97M 55.06%	-12.31M 106.03%	-13.78M 11.94%	1.75M 112.72%
stock based compensation	6K -	28K 366.67%	33K 17.86%	52K 57.58%	56K 7.69%	127K 126.79%	230K 81.10%	368K 60%	329K 10.60%	155K 52.89%
change in working capital	-69K -	14K 120.29%	-162K 1,257.14%	-452K 179.01%	135K 129.87%	111K 17.78%	-157K 241.44%	233K 248.41%	-446K 291.42%	-744K 66.82%
accounts receivables			-150K -	-491K 227.33%	80K 116.29%	176K 120%	-228K 229.55%	235K 203.07%	-456K 294.04%	26K 105.70%
inventory
accounts payables			-12K -	39K 425%	55K 41.03%	-65K 218.18%	71K 209.23%	-2K 102.82%	10K 600%	23K 130%
other working capital										-793K -
other non cash items	26K -	-1.42M 5,565.38%	-1.81M 27.30%	-2.04M 13.05%	-4K 99.80%	-12K 200%	-48K 300%	-9K 81.25%	-1K 88.89%	-50K 4,900%
net cash provided by operating activities	-617K -	-730K 18.31%	-805K 10.27%	-1.21M 50.81%	-970K 20.10%	-1.27M 30.93%	-1.76M 38.43%	-1.47M 16.61%	-3.01M 105.05%	-3.25M 8.05%
investments in property plant and equipment	-3K -	-1K 66.67%	-2K 100%	-5K 150%	-7K 40%	-7K 0%	-3K 57.14%	-12K 300%	-3K 75%	-16K 433.33%
acquisitions net							-567K -	-71K 87.48%	5.91M 8,425.35%
purchases of investments	-26K -	-33K 26.92%	-5K 84.85%	-33K 560%	-245K 642.42%	-779K 217.96%	-97K 87.55%	-71K 26.80%	-614K 764.79%	-691K 12.54%
sales maturities of investments							40K -	-1.55M 3,967.50%	6.53M 521.78%	4.93M 24.51%
other investing activites					4K -	14K 250%	27K 92.86%	9K 66.67%	-6.44M 71,622.22%	-834K 87.04%
net cash used for investing activites	-29K -	-34K 17.24%	-7K 79.41%	-38K 442.86%	-248K 552.63%	-772K 211.29%	-600K 22.28%	-1.69M 182%	5.38M 418.09%	3.38M 37.11%
debt repayment
common stock issued	1.14M -	854K 25.22%	1.00M 17.45%	3M 199.10%		2.55M -	4.17M 63.60%	2.33M 44.10%		98K -
common stock repurchased
dividends paid
other financing activites	-64K -	-41K 35.94%	-56K 36.59%	-190K 239.29%		-155K -	-315K 103.23%	-152K 51.75%
net cash used provided by financing activities	1.08M -	813K 24.58%	947K 16.48%	2.81M 196.73%		2.40M -	3.86M 61.03%	2.18M 43.47%		98K -
effect of forex changes on cash
net change in cash	432K -	49K 88.66%	135K 175.51%	1.56M 1,054.07%	-1.22M 178.18%	355K 129.15%	1.50M 323.10%	-976K 164.98%	2.38M 343.44%	235K 90.11%
cash at beginning of period	155K -	587K 278.71%	636K 8.35%	771K 21.23%	2.33M 202.08%	1.11M 52.30%	1.47M 31.95%	2.97M 102.46%	1.99M 32.88%	4.37M 119.28%
cash at end of period	587K -	636K 8.35%	771K 21.23%	2.33M 202.08%	1.11M 52.30%	1.47M 31.95%	2.97M 102.46%	1.99M 32.88%	4.37M 119.28%	4.60M 5.38%
operating cash flow	-617K -	-730K 18.31%	-805K 10.27%	-1.21M 50.81%	-970K 20.10%	-1.27M 30.93%	-1.76M 38.43%	-1.47M 16.61%	-3.01M 105.05%	-3.25M 8.05%
capital expenditure	-3K -	-1K 66.67%	-2K 100%	-5K 150%	-7K 40%	-7K 0%	-3K 57.14%	-12K 300%	-3K 75%	-16K 433.33%
free cash flow	-620K -	-731K 17.90%	-807K 10.40%	-1.22M 51.05%	-977K 19.85%	-1.28M 30.71%	-1.76M 37.90%	-1.48M 16.07%	-3.01M 103.59%	-3.26M 8.47%

FIPP

UK:CO:FRONTIERIP

Frontier IP Group Plc

Last Close

29.00

25/11 09:23

Market Cap

194.56K

Beta: -

Volume Today

49.24K

Avg: -

Preview